EQS-Adhoc

European Healthcare Acquisition & Growth Company B.V. removes shareholders’ votes on proposed business combination with Croma-Pharma GmbH from agenda of general meeting

EQS-Ad-hoc: European Healthcare Acquisition & Growth Company B.V. / Key word(s): AGM/EGM European Healthcare Acquisition & Growth Company B.V. removes shareholders’ votes on proposed business combination with Croma-Pharma GmbH from agenda of general meeting 26-Jun-2023 / 19:15 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. NOT FOR DISTRIBUTION, PUBLICATION OR FORWARDING, EITHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PUBLICATION.

 

Public disclosure of inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation)

 

European Healthcare Acquisition & Growth Company B.V. removes shareholders’ votes on proposed business combination with Croma-Pharma GmbH from agenda of general meeting

 

Munich, June 26, 2023

 

European Healthcare Acquisitions & Growth Company B.V. (EHC) removes the voting items 8 up to and including 18 relating to the proposed business combination, in particular, the entering into and approval of the business combination with Croma-Pharma GmbH (Croma) from the agenda of the general meeting taking place on June 27, 2023 as a virtual general meeting.

 

EHC’s today’s decision to remove these agenda items is based on the results of the redemption period and secured private investments in public equity (PIPE) proceeds communicated on June 23, 2023 as well as further discussions with potential investors, EHC’s shareholders, Croma and the Croma shareholders. Such discussions did not result in sufficient PIPE proceeds or a further amendment of the minimum cash condition.